Loading...
Loading...
TNGX| Name | Value |
|---|---|
| Revenues | 53.8M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 39.7M |
| Operating I/L | 14.1M |
| Other Income/Expense | 1.8M |
| Interest Income | 1.1M |
| Pretax | 15.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 15.9M |
Tango Therapeutics, Inc. is a biotechnology company specializing in the discovery and development of cancer drugs. Its lead program, TNG908, is a synthetic lethal small molecule inhibitor targeting protein arginine methyltransferase 5 for cancers with methylthioadenosine phosphorylase deletions. The company also develops inhibitors for BRCA1 or BRCA2-mutant cancers and STK11-mutant cancers. Tango Therapeutics has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of cancer therapies.
